Effects of 4-1BB signaling on the biological function of murine dendritic cells

Oncology Letters

Volumn 3, Issue 2, 2012, Pages 477-481

  Kuang, Youlin ^a   Weng, Xiaodong ^a   Liu, Xiuheng ^a   Zhu, Hengchen ^a   Chen, Zhiyuan ^a   Chen, Hui ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

4 1BB; Co stimulatory molecules; Dendritic cells

Indexed keywords

B7 ANTIGEN; CD137 ANTIGEN; CD86 ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 6; LYMPHOCYTE ANTIBODY; PROTEIN BCL 2; PROTEIN BCL XL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOREACTIVITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 84855252052     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.506     Document Type: Article

References (16)

1. Nencioni A, Grünebach F, Schmidt SM, et al: The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 65: 191-199, 2008.
2. Palucka K, Ueno H, Fay J and Banchereau J: Dendritic cells and immunity against cancer. J Intern Med 269: 64-73, 2011.
3. Nopora A and Brocker T: Bcl-2 controls dendritic cell longevity in vivo: J Immunol 169: 3006-3014, 2002.
4. Vinay DS and Kwon BS: Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells. Cell Immunol 192: 63-71, 1999.
5. Laderach D, Movassagh M, Johnson A, Mittler RS and Galy A: 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int Immunol 14: 1155-1167, 2002.
6. Lu ZY, Condomines M, Tarte K, et al: B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Exp Hematol 35: 443-453, 2007.
7. Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J and Kaufman HL: 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine 24: 4975-4986, 2006.
8. Xiao H, Huang B, Yuan Y, et al: Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 13: 1823-1830, 2007.
9. Lin GH, Liu Y, Ambagala T, Kwon BS, Ohashi PS and Watts TH: Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One 5: e11003, 2010.
10. Gullo C, Koh LK, Pang WL, Ho KT, Tan SH and Schwarz H: Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling. PLoS One 5: e10845, 2010.
11. Melero I, Shuford WW, Newby SA, et al: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3: 682-685, 1997.
12. Nagaraj S, Pisarev V, Kinarsky L, et al: Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother 30: 169-179, 2007.
13. O'Neill DW: Dendritic cells and T cells in immunotherapy. J Drugs Dermatol 9: 1383-1892, 2010.
14. Bertram EM, Dawicki W and Watts TH: Role of T cell costimulation in anti-viral immunity. Semin Immunol 16: 185-196, 2004.
15. Cannons JL, Choi Y and Watts TH: Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response. J Immunol 165: 6193-6204, 2000.
16. Cannons JL, Hoeflich KP, Woodgett JR and Watts TH: Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB. J Immunol 163: 2990-2998, 1999.